- Home
- FHTX vs SIGA Comparison
FHTX vs SIGA Comparison
Compare FHTX & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- SIGA
- Stock Information
- Founded
- FHTX 2015
- SIGA 1995
- Country
- FHTX United States
- SIGA United States
- Employees
- FHTX N/A
- SIGA N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- FHTX Health Care
- SIGA Health Care
- Exchange
- FHTX Nasdaq
- SIGA Nasdaq
- Market Cap
- FHTX 513.7M
- SIGA 551.0M
- IPO Year
- FHTX 2020
- SIGA 1997
- Fundamental
- Price
- FHTX $7.84
- SIGA $6.48
- Analyst Decision
- FHTX Strong Buy
- SIGA
- Analyst Count
- FHTX 5
- SIGA 0
- Target Price
- FHTX $16.00
- SIGA N/A
- AVG Volume (30 Days)
- FHTX 125.4K
- SIGA 542.0K
- Earning Date
- FHTX 11-04-2024
- SIGA 11-07-2024
- Dividend Yield
- FHTX N/A
- SIGA 9.26%
- EPS Growth
- FHTX N/A
- SIGA N/A
- EPS
- FHTX N/A
- SIGA 1.20
- Revenue
- FHTX $25,515,000.00
- SIGA $173,731,386.00
- Revenue This Year
- FHTX N/A
- SIGA $16.98
- Revenue Next Year
- FHTX $8.77
- SIGA $16.49
- P/E Ratio
- FHTX N/A
- SIGA $5.42
- Revenue Growth
- FHTX N/A
- SIGA 399.31
- 52 Week Low
- FHTX $2.70
- SIGA $4.26
- 52 Week High
- FHTX $10.25
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- FHTX 44.02
- SIGA 43.28
- Support Level
- FHTX $7.33
- SIGA $6.02
- Resistance Level
- FHTX $8.25
- SIGA $7.89
- Average True Range (ATR)
- FHTX 0.71
- SIGA 0.45
- MACD
- FHTX -0.13
- SIGA -0.06
- Stochastic Oscillator
- FHTX 21.52
- SIGA 28.02
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.